314 related articles for article (PubMed ID: 23665966)
41. Colorectal cancer surveillance in patients with inflammatory bowel disease and primary sclerosing cholangitis: an economic evaluation.
Negrón ME; Kaplan GG; Barkema HW; Eksteen B; Clement F; Manns BJ; Coward S; Panaccione R; Ghosh S; Heitman SJ
Inflamm Bowel Dis; 2014 Nov; 20(11):2046-55. PubMed ID: 25230162
[TBL] [Abstract][Full Text] [Related]
42. Smoking and colorectal neoplasia in patients with inflammatory bowel disease: Dose-effect relationship.
Wijnands AM; Elias SG; Dekker E; Fidder HH; Hoentjen F; Ten Hove JR; Maljaars PWJ; van der Meulen-de Jong AE; Mooiweer E; Ouwehand RJ; Penning de Vries BBL; Ponsioen CY; van Schaik FDM; Oldenburg B;
United European Gastroenterol J; 2023 Sep; 11(7):612-620. PubMed ID: 37505117
[TBL] [Abstract][Full Text] [Related]
43. Primary sclerosing cholangitis and bile acids.
Chazouillères O
Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S21-5. PubMed ID: 23141889
[TBL] [Abstract][Full Text] [Related]
44. Statin Exposure Is Not Associated with Reduced Prevalence of Colorectal Neoplasia in Patients with Inflammatory Bowel Disease.
Shah SC; Glass J; Giustino G; Hove JRT; Castaneda D; Torres J; Kumar A; Elman J; Ullman TA; Itzkowitz SH
Gut Liver; 2019 Jan; 13(1):54-61. PubMed ID: 30400722
[TBL] [Abstract][Full Text] [Related]
45. [Treatment of cholestatic liver diseases with ursodeoxycholic acid].
Boberg KM; Schrumpf E
Tidsskr Nor Laegeforen; 1997 Sep; 117(23):3370-3. PubMed ID: 9411890
[TBL] [Abstract][Full Text] [Related]
46. Gender modifies the effect of ursodeoxycholic acid in a randomized controlled trial in colorectal adenoma patients.
Thompson PA; Wertheim BC; Roe DJ; Ashbeck EL; Jacobs ET; Lance P; Martínez ME; Alberts DS
Cancer Prev Res (Phila); 2009 Dec; 2(12):1023-30. PubMed ID: 19952360
[TBL] [Abstract][Full Text] [Related]
47. Colonic neoplasia in young patients with inflammatory bowel disease and primary sclerosing cholangitis.
Imam MH; Thackeray EW; Lindor KD
Colorectal Dis; 2013 Feb; 15(2):198-203. PubMed ID: 22712545
[TBL] [Abstract][Full Text] [Related]
48. Inflammatory bowel disease and liver transplantation for primary sclerosing cholangitis.
van de Vrie W; de Man RA; van Buuren HR; Schouten WR; Tilanus HW; Metselaar HJ
Eur J Gastroenterol Hepatol; 2003 Jun; 15(6):657-63. PubMed ID: 12840678
[TBL] [Abstract][Full Text] [Related]
49. Prevalence of inflammatory bowel disease in patients with primary sclerosing cholangitis: A systematic review and meta-analysis.
Zhang Y; Gao X; He Z; Jia H; Chen M; Wang X; Hong L; Cui Y; Wan J
Liver Int; 2022 Aug; 42(8):1814-1822. PubMed ID: 35689520
[TBL] [Abstract][Full Text] [Related]
50. Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis.
Lindström L; Hultcrantz R; Boberg KM; Friis-Liby I; Bergquist A
Clin Gastroenterol Hepatol; 2013 Jul; 11(7):841-6. PubMed ID: 23353641
[TBL] [Abstract][Full Text] [Related]
51. Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis.
de Vries AB; Janse M; Blokzijl H; Weersma RK
World J Gastroenterol; 2015 Feb; 21(6):1956-71. PubMed ID: 25684965
[TBL] [Abstract][Full Text] [Related]
52. A network meta-analysis of the efficacy and side effects of UDCA-based therapies for primary sclerosing cholangitis.
Zhu GQ; Shi KQ; Huang GQ; Wang LR; Lin YQ; Braddock M; Chen YP; Zhou MT; Zheng MH
Oncotarget; 2015 Sep; 6(29):26757-69. PubMed ID: 26378046
[TBL] [Abstract][Full Text] [Related]
53. Colorectal cancer in patients with inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis.
Vera A; Gunson BK; Ussatoff V; Nightingale P; Candinas D; Radley S; Mayer A; Buckels JA; McMaster P; Neuberger J; Mirza DF
Transplantation; 2003 Jun; 75(12):1983-8. PubMed ID: 12829898
[TBL] [Abstract][Full Text] [Related]
54. Incidence of colorectal cancer after liver transplantation for primary sclerosing cholangitis: a systematic review and meta-analysis.
Singh S; Edakkanambeth Varayil J; Loftus EV; Talwalkar JA
Liver Transpl; 2013 Dec; 19(12):1361-9. PubMed ID: 24019127
[TBL] [Abstract][Full Text] [Related]
55. Mortality and extraintestinal cancers in patients with primary sclerosing cholangitis and inflammatory bowel disease.
Ananthakrishnan AN; Cagan A; Gainer VS; Cheng SC; Cai T; Szolovits P; Shaw SY; Churchill S; Karlson EW; Murphy SN; Kohane I; Liao KP
J Crohns Colitis; 2014 Sep; 8(9):956-63. PubMed ID: 24559536
[TBL] [Abstract][Full Text] [Related]
56. A retrospective single-center review of primary sclerosing cholangitis in children.
Miloh T; Arnon R; Shneider B; Suchy F; Kerkar N
Clin Gastroenterol Hepatol; 2009 Feb; 7(2):239-45. PubMed ID: 19121649
[TBL] [Abstract][Full Text] [Related]
57. Duration of Inflammatory Bowel Disease Is Associated With Increased Risk of Cholangiocarcinoma in Patients With Primary Sclerosing Cholangitis and IBD.
Gulamhusein AF; Eaton JE; Tabibian JH; Atkinson EJ; Juran BD; Lazaridis KN
Am J Gastroenterol; 2016 May; 111(5):705-11. PubMed ID: 27002801
[TBL] [Abstract][Full Text] [Related]
58. Characteristics and clinical course of primary sclerosing cholangitis in France: a prospective cohort study.
Garioud A; Seksik P; Chrétien Y; Corphechot C; Poupon R; Poupon RE; Chazouillères O
Eur J Gastroenterol Hepatol; 2010 Jul; 22(7):842-7. PubMed ID: 19779305
[TBL] [Abstract][Full Text] [Related]
59. DNA content abnormality frequently develops in the right/proximal colon in patients with primary sclerosing cholangitis and inflammatory bowel disease and is highly predictive of subsequent detection of dysplasia.
Zhang R; Rabinovitch PS; Mattis AN; Lauwers GY; Choi WT
Histopathology; 2023 Jul; 83(1):116-125. PubMed ID: 37012656
[TBL] [Abstract][Full Text] [Related]
60. Non-IBD immunological diseases are a risk factor for reduced survival in PSC.
Rupp C; Mummelthei A; Sauer P; Weiss KH; Schirmacher P; Stiehl A; Stremmel W; Gotthardt DN
Liver Int; 2013 Jan; 33(1):86-93. PubMed ID: 23157607
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
